Electric pulse treatment through an endoscope for pancreatic tumors and cysts
Tests a needle that delivers electric pulses to pancreatic growths, in adults.
Plain-language title generated from the registry record
Registry title: Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Key facts
- Where
- Columbus, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed pancreatic cyst such as IPMN or a grade I neuroendocrine tumor who cannot have surgery.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- A pancreatic cyst such as IPMN at least 2 cm (0.8 in) across, or a WHO grade I neuroendocrine tumor at least 1 cm (0.4 in) across, confirmed by EUS-fine needle aspiration.
- Earlier treatment
- Not a candidate for surgery. One criterion mentions people who already had an attempt at ablation with EUS-RFA.
Main reasons for not taking part
- Severe or uncontrolled systemic disease, or lab results the investigator finds unsafe
- Pregnancy or breast-feeding
- Cannot have general anesthesia
- Life expectancy under 1 year
Read by machine on 9 November 2026.
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Trial code
- NCT07619417
- Record updated
- 13 October 2026
- Original description
This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.Read full original descriptionShow less
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation of Pancreatic Neoplasms - A Safety and Feasibility Trial
This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.
Inclusion: Age > 18 years; A diagnosis of a pancreatic neoplasm confirmed by EUS-fine needle aspiration (FNA) - (a) pancreatic cystic lesion such as intraductal papillary-mucinous neoplasm (IPMN), (b) World Health Organization (WHO) grade I neuroendocrine tumor; Lesion size estimation by computed tomography (CT) or magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) or EUS: (a) pancreatic cystic lesion such as IPMN - at least 2 cm in diameter. (b) WHO grade I neuroendocrine tumor - at least 1 cm in diameter; The patient is not a surgical candidate. Common clinical scenarios include -; Cirrhosis of the liver (common clinical scenario); Advanced (≥ 75 years) age (common clinical scenario); Morbid obesity; Significant cardiorespiratory comorbidity; Patient's choice (patient elects for non-surgical management); Other significant comorbid conditions that impose prohibitive surgical risks; The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery; For pancreatic neuroendocrine tumor (PNET) and all pancreatic cystic lesions (PCLs): Estimated life expectancy of at least 1 year; Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them; Women of childbearing potential must have a negative pregnancy test (serum/urine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy; The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-RFA (Ohio State University [OSU] Institutional Review Board [IRB] protocol: 2023C0004).
Exclusion: Any evidence of severe or uncontrolled systemic diseases, or laboratory findings that, in the investigator's opinion, make it unsafe for the patient to participate in the study study; Pregnancy or breast-feeding; Clinical frailty scale; Contraindication to general anesthesia after review by OSU Preoperative Assessment Clinic (OPAC).